483
Taro Pharmaceuticals Inc.Taro Pharmaceuticals Inc. – FDA 483, Sep 16, 2022
Record Details
An FDA inspection of Taro Pharmaceuticals Inc. in Brampton revealed significant deficiencies in manufacturing controls. The firm failed to establish adequate written procedures for in-process controls during packaging and did not consistently follow its own standard operating procedures for initiating and investigating deviations. These issues indicate a lack of robust quality system oversight.
View Company Profile
ID · bb5cda45-9f89-42a6-9724-d0f098043f78
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.